Compare KRT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRT | CGEM |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 999.4M |
| IPO Year | 2019 | 2020 |
| Metric | KRT | CGEM |
|---|---|---|
| Price | $52.63 | $15.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $46.50 | $34.60 |
| AVG Volume (30 Days) | 133.5K | ★ 712.5K |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ 4.70 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $467,743,000.00 | N/A |
| Revenue This Year | $12.22 | N/A |
| Revenue Next Year | $8.47 | $300.03 |
| P/E Ratio | $29.72 | ★ N/A |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $20.61 | $6.73 |
| 52 Week High | $56.06 | $23.19 |
| Indicator | KRT | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 49.86 |
| Support Level | $52.21 | $12.73 |
| Resistance Level | $55.36 | $16.31 |
| Average True Range (ATR) | 1.46 | 0.87 |
| MACD | -0.29 | 0.30 |
| Stochastic Oscillator | 17.95 | 82.28 |
Karat Packaging Inc is a distributor and manufacturer of disposable foodservice products and related items, including containers, bags, tableware, cups, lids, cutlery, straws, specialty beverage ingredients, gloves, and janitorial supplies, available in plastic, paper, biopolymer-based, and other compostable forms. The Company focuses on environmentally friendly products and provides customized solutions including product development, design, printing, and logistics services. It serves customers through chains and distributors, retail, and e-commerce/online, and operates in the manufacturing and distribution of single-use food and beverage products, as well as specialty food and beverage products and restaurant and warehouse supplies.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.